Showing posts with label Lung. Show all posts
Showing posts with label Lung. Show all posts

Thursday, 4 May 2017

Market Shares & Strategy Of Cardiac and Lung Surgical Robots During The Forecasts Period 2015 to 2021

Researchmoz added Most up-to-date research on "Market Shares & Strategy Of Cardiac and Lung Surgical Robots During The Forecasts Period 2015 to 2021" to its huge collection of research reports.

The 2015 study has 223 pages, 85 tables and figures. Worldwide Cardiac and Lung surgical robot markets are poised to achieve significant growth as next generation systems provide a way to improve traditional open surgery and decrease the number of ports needed for minimally invasive surgery.

The automated process revolution in surgery and communications is being implemented via robots. Robots automation of systems is providing significant improvement in the accuracy of surgery and the repeatability of process.
Intuitive Surgical owns the market as the major participant with compelling market share in cardiac and lung surgical robots. This leadership position will need to be defended as other vendor products, now in clinical trials come to market. Advanced technology, an installed base and a well trained core group of surgeons give Intuitive Surgical market advantage.
Patients for some types of procedures fare better when the heart or lung surgery is done by surgical robots. The documentation of improvements in care delivery, the ability to ensure better outcomes from surgery promise that cardiac and lung surgical robotics is a strong growth market.
Heart disease is still the largest disease worldwide. The issue for cardiac and lung robotic surgery is that so many heart patients exist.
Every leading surgeon working to perform heart and lung robotic surgery has worked to be accepted to practice at a hospital that has those robotic devices. The really talented surgeons depend on hospitals having the cardiac robotic equipment. In order to attract physicians and patients, the hospitals have to purchase the surgical equipment.
The market penetration of the cardiac and lung surgical robots will go to 100 percent in the US top hospitals within five years. As the surgeons migrate to the places that have the robotic surgical equipment, other hospitals and their potential patient populations notice. If the hospital does not have the surgical robotic equipment, it will not have any surgeons, this is a bad situation for a hospital. The cardiac and lung robotic surgical equipment permits better surgery and the surgeons and patients know this.


Cardiac and lung robotic surgery is poised to eclipse open surgery. It is used in the categories of lobectomy, thoracic revascularization, and mitral valve repair surgery. Surgical robots are positioned to become the standard of care for hospitals in the delivery of some heart surgery. The emerging group of several surgical robotic companies will collectively have enough marketing dollars and enough marketing clout to drive replacement of virtually all open cardiac and lung surgery.
Larger hospitals that can afford the expenditure are adopting heart and lung robotic surgical devices to improve their outcomes numbers. Hospitals are measured on outcomes, robots for surgery, when used by a trained physician are improving outcomes significantly. Hospital robotic systems have an emphasis on outcomes improvement during surgery. This has resulted in investment in robotics technology that is useful, and achieves positive patient outcomes.
Technology is enhancing a wide variety of procedures in many cardiac surgical specialties. Cardiac and thoracic surgeons at leading hospitals use robotic surgical systems increasingly. The aim is to perform more of the one-hundred thousand MIS surgical procedures of various types using robots. The surgeries performed by robot include cardiothoracic and vascular surgery. These surgical applications are cleared by the FDA.
“Existing open cardiac and lung surgery can be replaced in some part by robotic surgery during the forecast period. Cardiac and lung robotic surgical approaches complement existing open surgery techniques. Soon, all surgery will be undertaken with at least come aspects of robotic surgery replacing or complementing open surgery.”
Companies Profiled
  • Intuitive Surgical
Market Participants
  • Chinese Surgical Robots
  • Corindus
  • Freehand
  • Johnson and Johnson / DePuy Synthes
  • Google / Johnson & Johnson / Ethicon
  • Medrobotics
  • Medtronic

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=488239

Wednesday, 29 March 2017

Global Therapeutic Landscape Of Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2018

Researchmoz added Most up-to-date research on "Global Therapeutic Landscape Of Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2018" to its huge collection of research reports.

Global Markets Directs, Squamous Non-Small Cell Lung Cancer Pipeline Review, H1 2015, provides an overview of the Squamous Non-Small Cell Lung Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Squamous Non-Small Cell Lung Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=245114

  • The report reviews key players involved in the therapeutics development for Squamous Non-Small Cell Lung Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics

Friday, 24 March 2017

Pipeline Analysis Of Small Cell Lung Cancer (SCLC) Market - Insights, Epidemiology And Forecast To 2023

ResearchMoz presents this most up-to-date research on "Pipeline Analysis Of Small Cell Lung Cancer (SCLC) Market - Insights, Epidemiology And Forecast To 2023".

DelveInsights Small cell lung cancer (SCLC) - Market Insights, Epidemiology and Market Forecast-2023 Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Small cell lung cancer (SCLC) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Small cell lung cancer (SCLC) till 2023.

Key Coverage and Benefits


The report will help in developing business strategies by understanding the trends shaping and driving the global Small cell lung cancer (SCLC) market.
Identifying patient populations in the global Small cell lung cancer (SCLC)market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the best opportunities for Small cell lung cancer (SCLC) therapeutics in each of the markets covered.
To understand the future market competition in the global Small cell lung cancer (SCLC) therapeutics market and Insightful review of the key market drivers and barriers.

Scope

Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=774518

The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
It also provides Small cell lung cancer (SCLC) for United States, EU5 and Japan from 2013 and forecasted Market to 2023.

Table of Contents

Small cell lung cancer (SCLC) overview
Pathophysiology
Symptoms of disease
Etiology of disease
Diagnosis of disease
Treatment of disease
Overview of Marketed drugs
Drug Description
Mechanism of Action
Pharmacokinetics Properties
Marketed Details
Patent Information
Patent Exclusivity Expiry Assessment United States (US)
Patents Details
Historical and Forecasted sales of marketed molecules in the Global Small cell lung cancer (SCLC) Market
Global Epidemiology of Small cell lung cancer (SCLC) Forecasted to 2023
Global Market (2013-2015)
Global Forecasted Market (2016-2023)
Global Market by Geography
Market of US (2013-2015)
Forecasted Market of US (2016-2023)

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=774518

Wednesday, 22 March 2017

Growing popularity Of Global Lung Cancer Therapeutics Market For The Period 2017 - 2020

Researchmoz added Most up-to-date research on "Growing popularity Of Global Lung Cancer Therapeutics Market For The Period 2017 - 2020" to its huge collection of research reports.

Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly.

Technavios analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.

Covered in this report 
The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography: 
Americas
APAC
EMEA

Technavio's report, Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 

F. Hofmann-La Roche
Eli Lilly
AstraZeneca
Pfizer
Celgene

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=877716

Other prominent vendors 

Abbvie
Aetna
Agennix
Allergan
Amgen
ARIAD Pharmaceuticals
Astellas Pharma
Betta Pharmaceuticals
BeyondSpring Pharmaceuticals
BioNumerik Pharmaceuticals
Boehringer Ingelheim
Boston Biomedical
Bristol-Myers Squibb
Celldex
CTI BioPharma
Eisai
GlaxoSmithKline
GTx
Helsinn
Hutchison Medipharma
Ionis Pharmaceuticals
Kadmon Corporation
MabVax
Merck
Novartis
NovaRx Corporation
OncoGeneX
Ono Pharmaceutical
OSE Immunotherapeutics
OSI Pharmaceuticals
Peregrine
PharmaMar
Pierre Fabre
Qiagen
Recombio
Samsung Bioepis
Sanofi
SFJ Pharmaceuticals
Spectrum Pharmaceuticals
Sumitomo Dainippon Pharma
Synta
Takeda Pharmaceuticals
Teva Pharmaceutical
Xcovery

Market driver 

Growing demand for targeted therapies
For a full, detailed list, view our report 

Market challenge 
Growing popularity of alternative therapeutics 
For a full, detailed list, view our report 

Market trend 
Emergence of nanomedicine platform for the treatment of lung cancer
For a full, detailed list, view our report 

Key questions answered in this report 
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors? 

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=877716

Monday, 2 January 2017

Pipeline Review, H2 2017- Non-Small Cell Lung Cancer | ResearchMoz

Researchmoz added Most up-to-date research on "Pipeline Review, H2 2017- Non-Small Cell Lung Cancer | ResearchMoz" to its huge collection of research reports.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer Pipeline Review, H2 2016, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 45, 178, 148, 1, 16, 156, 17 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 7, 37 and 7 molecules, respectively.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=905720

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=905720